Overview
Combining routine preoperative CT imaging with patient-specific computer modelling predicts the interaction between different sizes of transcatheter aortic valve replacement devices at different implantation depths and the patient's unique anatomy (including post-implantation deformation) allowing preoperative evaluation of the risk for paravalvular leakage and conduction disorders.
The objective of this randomized controlled trial is to evaluate whether pre-operative CT-imaging with advanced computer modelling and simulation (FEops HEARTguide™) adequately predicts procedural outcomes in TAVR procedures, whether it leads to changes of preoperative decisions and whether or not this leads to improved outcome in TAVR procedures.
Eligibility
Inclusion Criteria:
- Primary symptomatic severe aortic valve stenosis
- Accepted for TAVR, either by transfemoral, transsubclavian or transapical access
- Plan to implant one of the following transcatheter heart valves for which FEops HEARTguide™ is available (CoreValve™ Evolut™ R, and Evolut™ PRO and Evolut™ PRO+ (Medtronic, Minnesota, USA), ACURATE neo™ and ACURATE neo 2™ (Boston Scientific, Marlborough, MA, USA)
- Informed consent
Exclusion Criteria:a potential subject who meets any of the following criteria will be
excluded from participation in this study before randomization:
- Previous surgical aortic valve replacement
- Permanent pacemaker at baseline
- Emergency procedure
- Poor CT image quality (disabling computer-simulation, i.e. generation of 3D anatomical
models will not be possible with poor CT image quality), for example because of motion
artifacts due to the presence of other implanted devices affecting the region of
interest
- Patient who did not agree to the informed consent and/or refused to participate
- Patient unable to understand the informed consent/study